• Herbalife Q1 2026 earnings call drew CEO Stephan Gratziani, CFO John DeSimone, IR head Erin Banyas, with analysts from Citi, Jefferies, Maxim Group, Mizuho Securities, Water Tower Research.
• Net sales USD 1.3 billion rose 7.8% year over year; adjusted EBITDA USD 176 million topped guidance; India net sales hit record USD 275 million, up about 32%.
• Completed USD 1.45 billion senior secured refinancing in April, targeting about USD 45 million in annual cash interest savings; ended quarter with total leverage ratio 2.7x, net leverage 2.1x, targeting net leverage below 2x by end-2026.
• Closed Bioniq core personalized nutrition asset purchase April 30 with USD 55 million base consideration payable over five years, up to USD 95 million contingent; distributors to offer Bioniq personalized supplements across 11 European countries in late June, US rollout in July.
• Raised constant-currency sales outlook midpoint while keeping reported sales growth view at 1.5%-5.5%; management said Pro2col remains in beta with no direct revenue assumed in forecasts, while higher oil costs are being absorbed with no price increase tied to it.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Herbalife Ltd. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.